Place Raymond Blyckaerts, 13
B-1050 Brussels, Belgium

Opening hours:
Mon to Thu: 10h - 12h30 and 13h30 - 17h
Fri: 10h - 12h30 and 13h30 - 16h

Google maps

Find us on
Google Maps
To subscribe to our newsletter, please click here. If you would like to become an EATG member, please fill in the form here. You can also subscribe to our RSS feed by clicking here.
You can also follow us on one of these media :

Treatment of latent tuberculosis infection: A network meta-analysis

In many countries with a low incidence of tuberculosis (TB), many new cases emerge as a result of reactivation of latent TB infection (LTBI), which is often acquired in high-incidence areas or from recent exposure in occasional outbreaks. Therefore, such countries have had a renewed interest in LTBI screening and treatment, generally for groups at particularly high risk for...


Open Letter to President-elect Jean-Claude Juncker on move of medicinal products and health technologies to the portfolio of the Commissioner for internal market and industry

Brussels, 16 September 2014 - We are writing to express our astonishment and concern regarding your decision to move the competence for medicinal products and health technologies from the Commissioner in charge of Health to the Commissioner in charge of internal market and industry within the new Commission. Read the open letter here.


Source Source: EPHA

The genetics of coping with HIV

We respond to infections in two fundamental ways. One, which has been the subject of intensive research over the years, is "resistance," where the body attacks the invading pathogen and reduces its numbers. Another, which is much less well understood, is "tolerance," where the body tries to minimise the damage done by the pathogen. Now an elegant study using data from a...


Source Source: ScienceDaily

HIV controllers respond better to hepatitis B vaccine

HIV positive natural controllers who maintain undetectable or low viral load without antiretroviral therapy (ART) are more likely to achieve adequate response to hepatitis B virus (HBV) vaccination and have improved survival, according to a study published in the  August 21 edition of the open-access journal  PLoS ONE . Due to similar transmission routes,...


Sofosbuvir/ledipasvir reduced HCV-related liver complications

NEW YORK — The NS5A and NS5B inhibitors ledipasvir/sofosbuvir reduced the incidence of compensated and decompensated cirrhosis, hepatocellular carcinoma and liver transplant in patients with hepatitis C virus compared with sofosbuvir with pegylated interferon plus ribavirin, according to data presented at AASLD/EASL Special Conference on Hepatitis C. Researchers in the United...


Source Source: Healio